iSpecimen Inc. (ISPC) stock
ISPCNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 7/3028% below fair value
$0.70−0.01 (-1.82%)
Close on Nov 12, 2026Market cap $1.75MP/E –Yield –
iSpecimen r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2024 it was $1.49M, down 7.8% from the year before. The highest annual figure on record is $1.62M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.49M | -7.8% |
| FY2023 | Dec 31, 2023 | $1.62M | +9.9% |
| FY2022 | Dec 31, 2022 | $1.47M | +67.6% |
| FY2021 | Dec 31, 2021 | $879.24K | +175.4% |
| FY2020 | Dec 31, 2020 | $319.24K | – |
See a number that looks wrong?